Trimethoprim in pediatric urinary tract infection

Child Nephrol Urol. 1988-1989;9(1-2):77-81.

Abstract

The efficacy of trimethoprim (TMP) as a single therapeutic agent in the treatment of urinary tract infection (UTI) in children was studied in 112 children prospectively comparing TMP against trimethoprim-sulfamethoxazole (TMP/Sulfa), sulfamethoxazole and ampicillin. Children with repeated colony counts of greater than 100,000 CFU/ml of the same organism grown in 2-3 consecutive clean catch specimens were successively assigned to each treatment group for 10 days' therapy. TMP achieved a cure rate of 100% compared to TMP/Sulfa 100% (p greater than 0.05), sulfamethoxazole 93% (p less than 0.05) and ampicillin 63% (p less than 0.01). TMP and TMP/Sulfa groups had no failures while sulfamethoxazole and ampicillin groups had 7% (p less than 0.05) and 37% (p less than 0.01), respectively. Relapses occurred in 4% of the TMP group whereas TMP/Sulfa had 7% (p greater than 0.05); sulfamethoxazole and ampicillin groups had none. TMP group had 7% recurrence compared to 6% TMP/Sulfa, 4% sulfamethoxazole and 7% ampicillin (p greater than 0.05). Gastrointestinal side effects and skin rashes were not encountered in the TMP group; depression of WBC was the lowest in this group. As a single therapeutic agent, TMP appears to be safe and efficacious for treatment of acute UTI in children.

Publication types

  • Comparative Study

MeSH terms

  • Ampicillin / therapeutic use
  • Child
  • Child, Preschool
  • Drug Combinations
  • Drug Evaluation
  • Female
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Sulfamethoxazole / therapeutic use*
  • Trimethoprim / therapeutic use*
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / microbiology

Substances

  • Drug Combinations
  • Ampicillin
  • Trimethoprim
  • Sulfamethoxazole